financetom
Business
financetom
/
Business
/
Update: Market Chatter: French Antitrust Regulators Readying Nvidia Charges
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Update: Market Chatter: French Antitrust Regulators Readying Nvidia Charges
Jul 1, 2024 9:18 AM

11:56 AM EDT, 07/01/2024 (MT Newswires) -- (Adds Nvidia declining comment in fourth paragraph, more detail throughout.)

Nvidia ( NVDA ) will be charged with anticompetitive practices by French regulators, Reuters reported Monday, citing people with direct knowledge of the matter.

The move follows a September, 2023 raid by investigators from the Autorite de la Concurrence, France's competition authority, on a company - identified in media reports at the time as Nvidia ( NVDA ) - "suspected of having implemented anticompetitive practices in the graphics cards sector."

The French competition authority said an investigation does not "pre-suppose" a specific violation of the law or the existence of a larger investigation, if appropriate. The agency also did not identify the subject of its probe.

Nvidia ( NVDA ) declined to comment on the report when contacted Monday by MT Newswires.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Price: 123.22, Change: -0.32, Percent Change: -0.26

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
HilleVax Q4 Net Loss Widens; Shares Extend Decline After Hours
HilleVax Q4 Net Loss Widens; Shares Extend Decline After Hours
Mar 20, 2024
05:49 PM EDT, 03/20/2024 (MT Newswires) -- HilleVax ( HLVX ) reported a Q4 net loss late Wednesday of $0.78 per diluted share, compared with a loss of $0.56 a year earlier. Analysts polled by Capital IQ expected a loss of $0.83. As expected, no revenue for the quarter ended Dec. 31 was reported. The clinical-stage biopharmaceutical company said it...
HilleVax Proposes $500 Million Offering of Equity, Debt Securities in Shelf Registration
HilleVax Proposes $500 Million Offering of Equity, Debt Securities in Shelf Registration
Mar 20, 2024
05:49 PM EDT, 03/20/2024 (MT Newswires) -- HilleVax ( HLVX ) said late Wednesday it may sell $500 million of securities in one or more offerings, according to a shelf filing with regulators. The company may sell common and preferred stock, debt securities, warrants and units from time to time. Shares of the company fell 1.4% lower in after-hours activity....
CERAWEEK-Shippers turn to longer-term leases as tanker supply tightens
CERAWEEK-Shippers turn to longer-term leases as tanker supply tightens
Mar 20, 2024
By Arathy Somasekhar and Georgina McCartney HOUSTON, March 20 (Reuters) - Rising oil tanker chartering rates due to global shipping disruption are forcing oil shippers to take on longer-term shipping charters, executives said this week at an energy conference in Houston. The global oil tanker fleet must now travel further to get crude to refineries and fuel to consumers. European...
Bristol-Myers Squibb's Multiple Myeloma Treatment Gets European Commission Approval
Bristol-Myers Squibb's Multiple Myeloma Treatment Gets European Commission Approval
Mar 20, 2024
05:44 PM EDT, 03/20/2024 (MT Newswires) -- Bristol-Myers Squibb ( BMY ) said late Wednesday the European Commission approved Abecma to treat adult patients with relapsed and refractory multiple myeloma who have received at least two previous therapies. The approval covers patients who have shown disease progression on the last therapy, the company said. Abecma has maintained its orphan designation...
Copyright 2023-2026 - www.financetom.com All Rights Reserved